"Gerald E. Commissiong, President & CEO of Amarantus, will provide a corporate update and a review of the Amarantus Diagnostics business and development strategy for the company's therapeutic programs with a focus on investigational drug, eltoprazine, for the treatment of Parkinson's disease levodopa-induced dyskinesias (PD-LID) , on Tuesday, February 10, 2015, at 8:30 a.m. Eastern Standard Time."


Near Term Catalysts:
IND Submission / Approval; Phase 2b in PD LID; End of Phase 2 meeting in Adult ADHD

Near-term Q1 Milestones Expected to Build Significant Momentum
Eltoprazine: IND submission
Eltoprazine: Initiate Phase 2b clinical trials

Investment Summary
Eltoprazine: Phase 2b-ready small molecule for PD LID
• Over 680 patients dosed to date, with strong safety profile
• Phase 2b initiation in process

http://content.stockpr.com/amarantus/media/23...9c4a0e.pdf (Slides 7, 56, 58)